Drug Trial Radar · NCT07868237
A Phase I Study to Investigate KH-001 in Healthy Males
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Nov 14, 2023
Primary completion
Aug 28, 2025
Study completion Aug 28, 2025
Sponsor
- Lead sponsor
- Kadence BioIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a Phase I, first-in-human study of KH-001 besylate in healthy male participants, conducted to investigate the safety, tolerability and pharmacokinetics (PK) of the study drug. The study was conducted in three parts: a single ascending dose (SAD) part, a multiple ascending dose (MAD) part, and a Formulation Effect part evaluating an orodispersible tablet (ODT) formulation. The study also evaluated the effect of KH-001 besylate on suicidality risk and mood. KH-001 besylate is being developed as an on-demand oral treatment for premature ejaculation.
Conditions
- Healthy Male Volunteers
Interventions
KH-001 besylateDrug
Associated arm(s): 1 and 3
KH-001 besylate placeboDrug
Associated arm(s): Arm 2 (Placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through the final follow-up visit (up to Day 12)
- Number of Participants With Clinically Significant Abnormal Clinical Laboratory ValuesTime frame: From screening through the final follow-up visit (up to Day 12)
- Number of Participants With Clinically Significant Abnormal Vital SignsTime frame: From screening through the final follow-up visit (up to Day 12)
- Number of Participants With Clinically Significant Abnormal 12-Lead ECG FindingsTime frame: From screening through the final follow-up visit (up to Day 12)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec-Orion Clinical Pharmacology Unit
Merthyr Tydfil, South Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.